Over the past 12 months, Vertex Pharmaceuticals (VRTX) has significantly underperformed the broader market. Since March 2025, the company’s stock price has declined by a cumulative 10%, while the S&P 500 index rose by 15% over the same period. However, developments suggest that this biotechnology leader is poised for a rebound. If that proves to be the case, now may well be a favorable time to buy the stock. Let’s take a look at the potential trajectory of Vertex Pharmaceuticals over the coming year.
Vertex Pharmaceuticals’ revenue primarily comes from the sale of drugs that treat cystic fibrosis, a rare disease that affects the lungs and other organs, leading to breathing difficulties. The company’s most important therapy for cystic fibrosis is Trikafta, which covers up to 90% of patients, along with the newer drug Alyftrek, which offers the added advantage of once-daily dosing.
These two products continue to drive revenue growth. In 2025, Vertex’s revenue increased by 9% year-over-year to $12 billion. Over the next 12 months, they will continue to serve as the company’s core business pillars. Vertex is currently the only player in the global cystic fibrosis drug market, and there remains considerable room for expansion. It is anticipated that revenue from its core cystic fibrosis business could grow at a high-single-digit or low-double-digit rate in the coming year.
Vertex Pharmaceuticals expects that its new products—including Journavx for acute pain and Casgevy, a gene-editing therapy for sickle cell disease and beta-thalassemia—will contribute at least $500 million in revenue this year. This would represent a strong performance from the company’s non-cystic fibrosis portfolio and may well mark the beginning of a new era. Over the next year, the biotechnology company could achieve several important milestones in pipeline advancement and regulatory approvals.
First, povetacicept, a drug for the treatment of IgA nephropathy, has shown favorable results in a Phase 3 clinical study. Vertex plans to submit a marketing application by the end of March, meaning the drug could receive regulatory approval by the end of the year or in early 2027. Additionally, Vertex expects to release Phase 3 clinical trial data this year for inaxaplin, an investigational drug for the treatment of APOL-1-mediated kidney disease. If the data are positive, the company will seek regulatory approval, which could potentially be achieved later next year. Finally, Vertex plans to submit a marketing application this year for zimislecel, a therapy for type 1 diabetes. By March 2027, Vertex Pharmaceuticals’ product portfolio could include one entirely new drug, with two more awaiting approval.
With its robust cystic fibrosis business and these potential new approvals, the biotechnology company’s long-term outlook appears very strong, positioning the stock as a compelling value at the current time.
